The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma Journal Article

Local Library Link: Find It @ Loyola

Authors: McDermott, D. F.; Cheng, S. C.; Signoretti, S.; Margolin, K. A.; Clark, J. I.; Sosman, J. A.; Dutcher, J. P.; Logan, T. F.; Curti, B. D.; Ernstoff, M. S.; Appleman, L.; Wong, M. K.; Khushalani, N. I.; Oleksowicz, L.; Vaishampayan, U. N.; Mier, J. W.; Panka, D. J.; Bhatt, R. S.; Bailey, A. S.; Leibovich, B. C.; Kwon, E. D.; Kabbinavar, F. F.; Belldegrun, A. S.; Figlin, R. A.; Pantuck, A. J.; Regan, M. M.; Atkins, M. B.
Article Title: The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
Abstract: PURPOSE: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2. EXPERIMENTAL DESIGN: Standard HD IL2 was administered to prospectively evaluate whether the ORR of patients with mRCC with "good" predictive pathologic features based on an "integrated selection" model [ISM (e.g., clear-cell histology subclassification and carbonic anhydrase-9 (CA-9) IHC staining] was significantly higher than the ORR of a historical, unselected population. Archived tumor was collected for pathologic analysis including tumor programmed death-ligand 1 (PD-L1) expression. RESULTS: One hundred and twenty eligible patients were enrolled between June 11 and September 7; 70% were Memorial Sloan Kettering Cancer Center (New York, NY) intermediate risk, 96% had clear cell RCC, and 99% had prior nephrectomy. The independently assessed ORR was 25% (30/120, 95% CI, 17.5%-33.7%, P = 0.0014; 3 complete responses, 27 partial responses) and was higher than a historical ORR. Thirteen patients (11%) remained progression free at 3 years and the median overall survival was 42.8 months. ORR was not statistically different by ISM classification ("good-risk" 23% vs. "poor-risk" 30%; P = 0.39). ORR was positively associated with tumor PD-L1 expression (P = 0.01) by IHC. CONCLUSIONS: In this prospective, biomarker validation study, HD IL2 produced durable remissions and prolonged survival in both "good" and "poor-risk" patients. The proposed ISM was unable to improve the selection criteria. Novel markers (e.g., tumor PD L1 expression) appeared useful, but require independent validation.
Journal Title: Clinical cancer research : an official journal of the American Association for Cancer Research
Volume: 21
Issue: 3
ISSN: 1078-0432; 1078-0432
Publisher: American Association for Cancer Research  
Journal Place: United States
Date Published: 2015
Start Page: 561
End Page: 568
Language: eng
DOI/URL:

10.1158/1078-0432.CCR-14-1520
Notes: LR: 20150204; CI: (c)2014; GR: P50 CA101942/CA/NCI NIH HHS/United States; GR: P50CA101942/CA/NCI NIH HHS/United States; JID: 9502500; 0 (Antineoplastic Agents); 0 (Interleukin-2); 0 (Recombinant Proteins); M89N0Q7EQR (aldesleukin); NIHMS645453; OID: NLM: NIHMS645453 [Available on 02/01/16]; OID: NLM: PMC4315731 [Available on 02/01/16]; PMCR: 2016/02/01 00:00; 2014/11/25 [aheadofprint]; ppublish